Interleukin Genetics reported a significant increase in revenue for the third quarter of 2016 compared with the same quarter of 2015.
For the quarter (end-September 30), the company reported total revenues of $734,000, compared with $296,000 for the fall quarter of 2015. Interleukin attributed the change to contracted research projects.
However, the company still reported an overall net loss of $1.99 million, down slightly from $2.03 million in the same quarter of 2015. Both research and development expenses and general and administrative expenses increased from the same quarter of last year.
